PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2017.0742018502398-404TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 StudyYung-Jue Bang, Toshimi Takano, Chia-Chi Lin, Adedigbo Fasanmade, Huyuan Yang, Hadi Danaee, Takayuki Asato, Thea Kalebic, Hui Wang, Toshihiko Doihttp://www.e-crt.org/upload/pdf/crt-2017-074.pdf, http://www.e-crt.org/journal/view.php?doi=10.4143/crt.2017.074, http://www.e-crt.org/upload/pdf/crt-2017-074.pdf
Annals of Oncology10.1093/annonc/mdu193.9201425ii108Phase I Study of the Investigational Anti-Guanylyl Cyclase C (GCC) Antibody-Drug Conjugate (ADC) Mln0264 in Adult Patients with Advanced Gastrointestinal Malignancies Expressing GCCJ.E. Faris, C. Cruz, K. Almhanna, W. Messersmith, J. Rodon, D.P. Ryan, J.A. Jung, A. Fasanmade, T. Wyant, T. Kalebichttps://api.elsevier.com/content/article/PII:S0923753419363197?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419363197?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/25/suppl_2/ii108/19446300/mdu193.9.pdf
Investigational New Drugs10.1007/s10637-017-0473-92017355634-641A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase CKhaldoun Almhanna, David Wright, Teresa Macarulla Mercade, Jean-Luc Van Laethem, Antonio Cubillo Gracian, Carmen Guillen-Ponce, Jason Faris, Carolina Muriel Lopez, Richard A. Hubner, Johanna Bendell, Alain Bols, Jaime Feliu, Naureen Starling, Peter Enzinger, Devalingham Mahalingham, Wells Messersmith, Huyuan Yang, Adedigbo Fasanmade, Hadi Danaee, Thea Kalebichttp://link.springer.com/article/10.1007/s10637-017-0473-9/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10637-017-0473-9.pdf, http://link.springer.com/content/pdf/10.1007/s10637-017-0473-9.pdf
Annals of Oncology10.1093/annonc/mdt202.30201324iv36Mln0264, an Investigational, First-In-Class Antibody-Drug Conjugate Targeting Guanylyl Cyclase C (Gcc): First-In-Human Study in Patients with Advanced Gastrointestinal MalignanciesWells Messersmith, Khaldoun Almhanna, Jordi Rodon, Cristina Cruz, David Ryan, JungAh Jung, Adedigbo Fasanmade, Tim Wyant, Thea Kalebichttps://api.elsevier.com/content/article/PII:S0923753419545689?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419545689?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/24/suppl_4/iv36/6676475/mdt202.30.pdf
Annals of Oncology10.1016/j.annonc.2021.05.150202132S130P-95 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including upper gastrointestinal cancersK. Muro, J. Bruce, J. Baranda, S. Gorla, C. Wu, F. Braitehhttps://api.elsevier.com/content/article/PII:S0923753421013399?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753421013399?httpAccept=text/plain
Investigational New Drugs10.1007/s10637-017-0439-y2017352235-241Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase CKhaldoun Almhanna, Maria Luisa Limon Miron, David Wright, Antonio Cubillo Gracian, Richard A. Hubner, Jean-Luc Van Laethem, Carolina Muriel López, Maria Alsina, Frederico Longo Muñoz, Johanna Bendell, Irfan Firdaus, Wells Messersmith, Zhan Ye, Adedigbo A. Fasanmade, Hadi Danaee, Thea Kalebichttp://link.springer.com/content/pdf/10.1007/s10637-017-0439-y.pdf, http://link.springer.com/article/10.1007/s10637-017-0439-y/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10637-017-0439-y.pdf
Annals of Oncology10.1016/s0923-7534(20)33497-9201223ix309Denosumab in Patients with Metastatic Prostate Cancer Previously Treated with Denosumab or Zoledronic Acid: 2-Year Open-Label Extension Phase Results from the Pivotal Phase 3 StudyK. Fizazi, J.E. Brown, M. Carducci, N.D. Shore, P. Sieber, F. Kueppers, L. Karsh, R. Wei, C. Goesslhttps://api.elsevier.com/content/article/PII:S0923753420334979?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420334979?httpAccept=text/plain
American Journal of Nephrology10.1159/00051807220211-10Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 StudyHiroyasu Yamamoto, Kiyoshi Nobori, Yoshimi Matsuda, Yasuhiro Hayashi, Takanori Hayasaki, Tadao Akizawahttps://www.karger.com/Article/Pdf/518072, https://www.karger.com/Article/Pdf/518072
SAGE Open Medicine10.1177/205031211878616120186205031211878616Iron parameters in patients with end-stage renal disease receiving lanthanum carbonate or other non-iron-based phosphate binders: Results from a phase 3, randomized open-label studyRosamund J Wilson, Beverly Jones, Claudio Marellihttp://journals.sagepub.com/doi/pdf/10.1177/2050312118786161, http://journals.sagepub.com/doi/full-xml/10.1177/2050312118786161, http://journals.sagepub.com/doi/pdf/10.1177/2050312118786161
Annals of Oncology10.1093/annonc/mdy283.131201829viii328EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)D.P. Petrylak, J. Rosenberg, I. Duran, Y. Loriot, G. Sonpavde, C. Wu, E. Gartner, A. Melhem-Bertrandt, T. Powleshttps://api.elsevier.com/content/article/PII:S0923753419493113?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419493113?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy283.131/26138912/mdy283.131.pdf